Understand the source comparison
Best Peptides for High Blood Pressure: Evidence Comparison
Lactotripeptides (VPP, IPP) ACE inhibition 2.6–7.5mg/day −3.7 / −2.0 mmHg (sys/dia) High. 18 RCTs, 1,060 participants Best-characterized oral peptides; consistent modest effect in mild hypertension Marine Collagen Hydrolysate eNOS activation, NO signaling 2.5–
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Lactotripeptides (VPP, IPP)
- ACE inhibition
- 2.6–7.5mg/day
- −3.7 / −2.0 mmHg (sys/dia)
- High. 18 RCTs, 1,060 participants
- Best-characterized oral peptides; consistent modest effect in mild hypertension
- Marine Collagen Hydrolysate
- eNOS activation, NO signaling
- 2.5–10g/day
- −2.9 / −1.5 mmHg
- Moderate. Heterogeneous mixtures, variable composition
- Requires high doses; effect modest but safe for long-term use
- Bonito Peptide (LKPNM)
- ACE inhibition + calcium channel modulation
- 1.5g/day
- −5.2 / −3.1 mmHg
- Moderate. 4 RCTs, mostly Asian populations
- Strong effect size but limited geographic validation
- Sardine Muscle Hydrolysate
- 3g/day
- −4.8 / −2.6 mmHg
- Low. 2 small trials, <100 participants
- Promising but requires larger validation studies
- TP508 (synthetic)
- NO enhancement, endothelial activation
- 0.1–0.5mg/kg subcutaneous
- Not directly studied for BP
- Low. Cardiovascular data extrapolated from wound healing trials
- Theoretical benefit; lacks hypertension-specific trials
- Soybean-Derived Peptides
- 5–10g/day
- −2.1 / −1.0 mmHg
- Moderate. 6 RCTs, inconsistent results
- High inter-study variability; may require specific genotypes (APOE polymorphisms) for response